NMN supplementation significantly increases NAD+ levels in postmenopausal women, improving muscle insulin sensitivity and energy markers, published in Science.
This pioneering study by Yoshino et al. (2021), published in Science, one of the most prestigious journals in the world, is the first randomized scientific trial to demonstrate in humans that oral supplementation with NMN (nicotinamide mononucleotide) significantly increases NAD+ levels in muscle tissue.
NAD+ (nicotinamide adenine dinucleotide) is a fundamental coenzyme present in all living cells, central to energy metabolism, DNA repair and the regulation of sirtuins, proteins linked to longevity. Its levels decline by 40 to 60% between ages 20 and 60.
This trial represents a decisive human proof of concept after years of promising results in animal models, paving the way for targeted supplementation strategies to counteract age-related energy decline.
Double-blind placebo-controlled RCT. 25 postmenopausal women (55–70 years) slightly overweight with prediabetes. 2 arms: NMN 250 mg/day for 10 weeks vs identical placebo. Muscle biopsies before and after.
NAD+ levels and metabolites by mass spectrometry in muscle biopsies. Hyperinsulinemic-euglycemic clamp to measure insulin sensitivity. DXA scan for body composition. VO2max by ergospirometry.
RNA-seq on muscle tissue to analyze transcriptomic changes induced by NMN. Identification of activated metabolic pathways: SIRT1/SIRT3, PGC-1α, mitochondrial respiratory chain, insulin/IGF-1 signaling pathways.
Weekly monitoring: CBC, hepatic, renal, lipid panels. Digestive tolerance questionnaires. No discontinuation of treatment due to side effects. Safety profile evaluated in all 25 participants.
This study published in Science marks a turning point in preventive aging medicine. For the first time in humans, it is demonstrated that simple oral supplementation can significantly raise NAD+ levels in target tissues, translating concretely into an improvement in energy metabolism comparable to that observed with regular physical exercise.
The 25% improvement in muscle insulin sensitivity is particularly important for our patients aged 45+: muscle insulin resistance is one of the first signs of metabolic aging, preceding type 2 diabetes by several decades. By correcting it via the restoration of NAD+, we act on a fundamental mechanism of aging, not on a symptom.
Activation of SIRT1 and PGC-1α is the signal that NMN does not just "fill" the NAD+ reservoir, it activates a cascade of cellular maintenance processes: DNA repair, mitochondrial biogenesis, epigenetic regulation. These mechanisms are at the heart of our regenerative medicine approach.
We integrate NMN into our micronutrition protocols after a complete biological assessment (NAD+ measurement, metabolic panel, epigenetic biological age) to personalize dosage and optimize efficacy according to each patient's profile.